



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-2008916

European Medicines Agency decision

EMA/PE/0000237903

of 16 April 2025

on the granting of a product specific waiver for padeliporfin (dipotassium) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

EMA/PE/0000237903

of 16 April 2025

on the granting of a product specific waiver for padeliporfin (dipotassium) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Steba Biotech S.A. on 22 November 2024 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2025 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

Article 1

A waiver for padeliporfin (dipotassium), the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Steba Biotech S.A., Rue Des Bains 14 A, 1212 Luxembourg, Luxembourg.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

EMADOC-1700519818-1802156
Amsterdam, 28 February 2025

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA/PE/0000237903

Scope of the application

Active substance(s):

Padeliporfin (dipotassium)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of upper tract urothelial cancer

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Steba Biotech S.A.

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Steba Biotech S.A. submitted to the European Medicines Agency on 22 November 2024 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 2 January 2025.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of upper tract urothelial cancer

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- powder for solution for injection, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of prostate cancer

Authorised indication(s):

- Monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and:
 - Clinical stage T1c or T2a,
 - Gleason Score ≤ 6 , based on high-resolution biopsy strategies,
 - PSA ≤ 10 ng/mL,
 - 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm³
- Invented name(s): Tookad
- Authorised pharmaceutical form(s): powder for solution for injection
- Authorised route(s) of administration: Intravenous use
- Authorised via centralised procedure.